动脉粥样硬化药物治疗概述及丹参酮的研究进展.ppt

Management of Atherosclerosis;Pathogenesis of Atherosclerosis;Mechanisms for the development of Atherosclerosis;Therapeutic targets of Atherosclerosis;TREATMENT OF HYPERLIPIDEMIA调血脂药;Lipoproteins: carriers of triglyceride and cholesterol;Classes of lipoproteins;LCAT：血浆卵磷脂胆固醇脂酰转移酶 CETP：胆固醇脂转蛋白;胆固醇合成抑制剂：HMG CoA reductase inhibitors Statins（他汀类） 胆汁酸吸收抑制剂：Bile acid sequestrants 胆固醇吸收抑制剂： Cholesterol absorption inhibitor Fibrates（贝特类） PCSK9抑制剂;HMG CoA：三羟基-三甲基戊二酰辅酶A还原酶;;;减少甘油三酯合成 降低胆固醇;PCSK9 ( pro-protein convertase subtilisin kexin 9，PCSK9 ) 前蛋白转化酶枯草溶菌素9 ;PCSK9 in the regulation of LDL;PCSK9 inhibitors;Treatment of atherosclerosis: Non-lipid targeting agents;Platelet activation;Danshen (丹参) ;Anti-atherosclerotic effects of Tanshinone IIA;Effects of Tanshinone IIA in atherosclerotic animal models;Effects of Tanshinone IIA in ApoE-/- mice fed with HCD;Necrotic core area;Effects of Tanshinone IIA in rats with atherosclerotic calcification;Effects of Tanshinone IIA in rabbits fed with high lipid diet;Effects of Tanshinone IIA on the lipid profile;In atherosclerotic rats;Tanshinone IIA inhibits oxLDL-induced LOX-1 expression via suppression of NF-κB;Effect of Tanshinone IIA on LOX-1 expressions;Effect of Tanshinone IIA on oxidative stress;Effect of Tanshinone IIA on oxLDL-induced NF-κB activation;Effect of Tanshinone IIA on foam cell formation;*;ERK/Nrf2/HO-1 is involved in effect of Tanshinone IIA on cholesterol accumulation;;Effect of Tanshinone IIA on expressions of scavenger receptors and cholesterol transporters in macrophages;Effect of Tanshinone IIA on expressions of HO-1 Nrf2;Tanshinone IIA regulates cholesterol metabolism via HO-1;Tanshinone IIA regulates Nrf2/HO-1 pathway via ERK;*;Conclusions